BioCentury
ARTICLE | Clinical News

Remofuscin regulatory update

December 9, 2013 8:00 AM UTC

Katairo said the European Commission granted Orphan Drug designation for Remofuscin to treat Stargardt's disease. The potassium-competitive acid blocker is in preclinical development. ...